Slowing the spread of treatment failure to artemisinin-based combination therapies in Uganda
Nature Communications·
- DOI
- 10.1038/s41467-026-74737-y
- PMID
- 42363010
- PMCID
- —
- OpenAlex
- W4410474510
- Study type
- Mathematical modelling
- Publisher
- Springer Science and Business Media LLC
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The work addresses an urgent regional challenge by quantifying how strategic antimalarial policy adjustments could preserve drug efficacy and reduce clinical failures over a six-year timeframe.
Structured evidence summary
Research question
How can alternative artemisinin-based combination therapy deployment strategies mitigate projected increases in treatment failure driven by emerging parasite resistance in Uganda?
Study design
The investigation utilizes a calibrated, individual-based computational simulation to track parasite transmission and evolutionary dynamics across multiple intervention scenarios.
Population and setting
The analysis focuses on the Ugandan public healthcare sector, specifically targeting populations affected by Plasmodium falciparum malaria carrying established resistance markers.
Main findings
Simulated policy shifts toward artesunate-amodiaquine are estimated to lower treatment failures by approximately thirty-five to thirty-eight percent compared to current regimens. A balanced multi-first-line approach yields roughly a thirty-six percent decline, while immediate introduction of a triple-combination regimen projects a forty-two percent reduction. Enhanced coverage of artesunate-amodiaquine emerges as a primary driver for near-term outcome improvements.
Public-health relevance
The work addresses an urgent regional challenge by quantifying how strategic antimalarial policy adjustments could preserve drug efficacy and reduce clinical failures over a six-year timeframe.
Important limitations
As a computational projection, the results depend entirely on underlying algorithmic parameters and assumed transmission conditions rather than observed clinical outcomes. The simulated timeline extends into the future, meaning actual implementation barriers and ecological variables remain unverified.
GIDS interpretation
This publication offers theoretical scenario planning for national malaria control programs, highlighting how modeled drug rotation and coverage metrics might influence resistance management pathways. It serves as a reference for policy development contexts rather than an indicator of current field monitoring trends.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 11 auditable classifier relationships to diseases, places, topics, and study design.